Equillium Competitors

Equillium (NASDAQ:EQ) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Equillium and Gossamer Bio, as reported by MarketBeat.com.

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Gossamer Bio has a consensus price target of $22.80, indicating a potential upside of 132.89%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Equillium.

Profitability

This table compares Equillium and Gossamer Bio's net margins, return on equity and return on assets.

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Earnings & Valuation

This table compares Equillium and Gossamer Bio's top-line revenue, earnings per share and valuation.

Equillium is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

31.1% of Equillium shares are owned by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are owned by institutional investors. 52.3% of Equillium shares are owned by company insiders. Comparatively, 23.3% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Equillium (NASDAQ:EQ) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Equillium and Provention Bio, as reported by MarketBeat.com.

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Provention Bio has a consensus price target of $30.75, indicating a potential upside of 139.67%. Given Provention Bio's higher probable upside, analysts plainly believe Provention Bio is more favorable than Equillium.

Profitability

This table compares Equillium and Provention Bio's net margins, return on equity and return on assets.

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500.

Earnings & Valuation

This table compares Equillium and Provention Bio's top-line revenue, earnings per share and valuation.

Provention Bio is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

31.1% of Equillium shares are owned by institutional investors. Comparatively, 39.4% of Provention Bio shares are owned by institutional investors. 52.3% of Equillium shares are owned by company insiders. Comparatively, 14.4% of Provention Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Equillium (NASDAQ:EQ) and OrganiGram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Equillium and OrganiGram, as reported by MarketBeat.com.

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. OrganiGram has a consensus price target of $2.93, indicating a potential downside of 4.87%. Given Equillium's stronger consensus rating and higher probable upside, equities analysts plainly believe Equillium is more favorable than OrganiGram.

Profitability

This table compares Equillium and OrganiGram's net margins, return on equity and return on assets.

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, OrganiGram has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Earnings & Valuation

This table compares Equillium and OrganiGram's top-line revenue, earnings per share and valuation.

Equillium has higher earnings, but lower revenue than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

31.1% of Equillium shares are owned by institutional investors. Comparatively, 10.8% of OrganiGram shares are owned by institutional investors. 52.3% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Equillium beats OrganiGram on 7 of the 13 factors compared between the two stocks.

Equillium (NASDAQ:EQ) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

31.1% of Equillium shares are held by institutional investors. 52.3% of Equillium shares are held by insiders. Comparatively, 13.0% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Equillium and AnaptysBio, as reported by MarketBeat.com.

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. AnaptysBio has a consensus price target of $26.4286, indicating a potential upside of 1.73%. Given Equillium's stronger consensus rating and higher probable upside, research analysts plainly believe Equillium is more favorable than AnaptysBio.

Profitability

This table compares Equillium and AnaptysBio's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Equillium and AnaptysBio's top-line revenue, earnings per share and valuation.

Equillium has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Summary

Equillium beats AnaptysBio on 8 of the 11 factors compared between the two stocks.

Equillium (NASDAQ:EQ) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

31.1% of Equillium shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 52.3% of Equillium shares are held by insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Equillium has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Equillium and Rigel Pharmaceuticals, as reported by MarketBeat.com.

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Rigel Pharmaceuticals has a consensus price target of $8.3333, indicating a potential upside of 101.29%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Equillium.

Profitability

This table compares Equillium and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Equillium and Rigel Pharmaceuticals' top-line revenue, earnings per share and valuation.

Equillium has higher earnings, but lower revenue than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Equillium (NASDAQ:EQ) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

31.1% of Equillium shares are held by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 52.3% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Equillium and Calliditas Therapeutics AB (publ), as reported by MarketBeat.com.

Equillium presently has a consensus price target of $14.00, indicating a potential upside of 84.45%. Calliditas Therapeutics AB (publ) has a consensus price target of $38.00, indicating a potential upside of 31.76%. Given Equillium's higher probable upside, research analysts plainly believe Equillium is more favorable than Calliditas Therapeutics AB (publ).

Profitability

This table compares Equillium and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Equillium and Calliditas Therapeutics AB (publ)'s top-line revenue, earnings per share and valuation.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Equillium. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Summary

Calliditas Therapeutics AB (publ) beats Equillium on 6 of the 10 factors compared between the two stocks.